PMID- 23712402
OWN - NLM
STAT- MEDLINE
DCOM- 20140121
LR  - 20130613
IS  - 1865-8652 (Electronic)
IS  - 0741-238X (Linking)
VI  - 30
IP  - 5
DP  - 2013 May
TI  - Immunogenicity and safety of a meningococcal serogroup A, C, Y and W 
      glycoconjugate vaccine, ACWY-TT.
PG  - 431-58
LID - 10.1007/s12325-013-0032-5 [doi]
AB  - A quadrivalent meningococcal serogroup A, C, W and Y conjugate vaccine (ACWY), 
      utilising tetanus toxoid (TT) as its carrier protein (ACWY-TT; Nimenrix, 
      GlaxoSmithKline Vaccines, Rixensart, Belgium) has been demonstrated to be safe 
      and immunogenic when administered to young children from 12 months of age, older 
      children, adolescents, and adults. Administration of a single dose of ACWY-TT 
      induces protective serum bactericidal antibodies against all four serogroups as 
      well as good antibody persistence. Coadministration studies have demonstrated 
      that ACWY-TT can be administered with diphtheria, tetanus, three-component 
      acellular pertussis, hepatitis B, inactivated polio virus and Haemophilus 
      influenzae type b conjugate vaccine (DTaP3-IPV-HBV/Hib, Infanrix hexa; 
      GlaxoSmithKline Vaccines, Rixensart, Belgium); measles, mumps, rubella, varicella 
      vaccine (Priorix-Tetra; GlaxoSmithKline Vaccines, Rixensart, Belgium); 10-valent 
      pneumococcal conjugate vaccine (Synflorix((R)); GlaxoSmithKline Vaccines, 
      Rixensart, Belgium); hepatitis A and B vaccine (Twinrix((R)); GlaxoSmithKline 
      Vaccines, Rixensart, Belgium); and seasonal influenza vaccine (Fluarix; 
      GlaxoSmithKline Vaccines, Rixensart, Belgium). Studies in young infants from 2 
      months of age have now commenced but immunisation with a single dose of ACWY-TT 
      from 12 months of age is a safe and immunogenic option in the prevention of 
      meningococcal disease.
FAU - Findlow, Helen
AU  - Findlow H
AD  - Vaccine Evaluation Unit, Health Protection Agency, Manchester Medical 
      Microbiology Partnership, PO Box 209, Clinical Sciences Building 2, Manchester 
      Royal Infirmary, Manchester, M13 9WZ, UK.
FAU - Borrow, Ray
AU  - Borrow R
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20130528
PL  - United States
TA  - Adv Ther
JT  - Advances in therapy
JID - 8611864
RN  - 0 (Meningococcal Vaccines)
RN  - 0 (Tetanus Toxoid)
RN  - 0 (Vaccines, Conjugate)
MH  - Humans
MH  - Meningococcal Infections/*prevention & control
MH  - Meningococcal Vaccines/immunology/*therapeutic use
MH  - Neisseria meningitidis, Serogroup A/immunology
MH  - Neisseria meningitidis, Serogroup C/immunology
MH  - Neisseria meningitidis, Serogroup W-135/immunology
MH  - Neisseria meningitidis, Serogroup Y/immunology
MH  - Tetanus Toxoid/immunology/*therapeutic use
MH  - Vaccines, Conjugate/immunology/*therapeutic use
EDAT- 2013/05/29 06:00
MHDA- 2014/01/22 06:00
CRDT- 2013/05/29 06:00
PHST- 2013/03/12 00:00 [received]
PHST- 2013/05/29 06:00 [entrez]
PHST- 2013/05/29 06:00 [pubmed]
PHST- 2014/01/22 06:00 [medline]
AID - 10.1007/s12325-013-0032-5 [doi]
PST - ppublish
SO  - Adv Ther. 2013 May;30(5):431-58. doi: 10.1007/s12325-013-0032-5. Epub 2013 May 
      28.